The comparison of two different direct acting antiviralregimens in treatment of chronic hepatitis C virus

Basit Öğe Kaydı
dc.contributor.authorİnce, Nevin
dc.contributor.authorPekgöz, Murat
dc.date.accessioned2023-07-26T11:58:49Z
dc.date.available2023-07-26T11:58:49Z
dc.date.issued2021
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractAim: Chronic hepatitis C virus (HCV) is considered a critical threat to the public health in the world. We compared treatment outcomesof Ombitasvir, Paritaprevir and Ritonavir with Dasabuvir (PrOD) and Ledipasvir (LDV) and Sofosbuvir (SOF) in real world patients with chronic HCV in treatment-naïve and pre-treated patients with chronic HCV.MaterialS and Methods: 91 adult patients enrolled in our study and were divided in two groups. The first group; consisted of 53patients, who orally received a fixed-dose combination tablet comprised of LDV and SOF once daily for 24 weeks. The second group; consisted of 38 patients, who orally received a fixed-dose combination tablet comprised of PrOD twice daily for 12 weeks without regard to fat or calorie content. Results: The results showed that sustained virologic response (SVR) rates were 100% in the both groups analyzed. 76 adverse eventswere occurred in total. 46 of overall adverse events were found on patients in the first group and 30 of those events were found on patients in the second group. Weakness (13.1%), pruritus (5.5%), myalgia (1.1%) nausea (5.5%), dry mouth (1.1%) and insomnia (1.1%) were observed among the patients. Twelve weeks after initiating treatment, virologic suppression was accomplished for all patients in the both groups. Additionally, laboratory analysis concluded that HCV-RNA levels of the overall patients were negative after 48 weeks of the onset of the treatment.Conclusion: The real world comparative analysis of two distinct treatment regimens concluded that administration of PrOD and LDV/ SOF on the patients with chronic HCV has an extremely effective outcome. SVR12 rates of 100% were obtained in both treatment regimens for all treatment naïve and treatment-experienced patients regardless of cirrhosis occurrence and of HCV genotype.en_US
dc.identifier.doi10.5455/annalsmedres.2020.09.963
dc.identifier.endpage1014en_US
dc.identifier.issn2636-7688
dc.identifier.issue5en_US
dc.identifier.startpage1009en_US
dc.identifier.trdizinid468503en_US
dc.identifier.urihttp://doi.org/10.5455/annalsmedres.2020.09.963
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/468503
dc.identifier.urihttps://hdl.handle.net/20.500.12684/13576
dc.identifier.volume28en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorİnce, Nevin
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.titleThe comparison of two different direct acting antiviralregimens in treatment of chronic hepatitis C virusen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
13576.pdf
Boyut:
303.88 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu